Eli Lilly
Gilead snaps up MiroBio and its checkpoint agonists for $405m
Phil Taylor
AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio
0 Comment
Chinese biotech Sironax raises $200m for RIPK1 pipeline
Phil Taylor
China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax
0 Comment
Market Access/ News/ News/ News/ Oncology
Roche’s fast-growing eye drug Vabysmo set for EU approval
Phil Taylor
Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo
0 Comment
Market Access/ News/ News/ News/ News/ Oncology/ Patients
Lilly’s Verzenios gets NICE blessing for early-stage breast cancer
Phil Taylor
breast cancer, Eli Lilly, HEOR, NHS, NICE, Oncology, Verzenio
0 Comment
Lilly partners with Sidekick in digital health alliance
Phil Taylor
breast cancer, digital, digital health, digital therapeutics, Eli Lilly, Oncology, partnering, Sidekick Health
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit
Phil Taylor
alopecia, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Olumiant, Pfizer
0 Comment
News/ News/ Sales and Marketing
Sanofi’s plans for OTC Cialis hit a snag in US
Phil Taylor
cialis, Eli Lilly, erectile dysfunction, OTC, Pfizer, Sanofi, Viagra
0 Comment
News/ News/ Sales and Marketing
Lilly sets aside $2.1bn for domestic investments
Phil Taylor
Eli Lilly, Indiana, investment, manufacturing
0 Comment